ATE232396T1 - Oxydiertes thymosin beta 4 - Google Patents
Oxydiertes thymosin beta 4Info
- Publication number
- ATE232396T1 ATE232396T1 AT99913428T AT99913428T ATE232396T1 AT E232396 T1 ATE232396 T1 AT E232396T1 AT 99913428 T AT99913428 T AT 99913428T AT 99913428 T AT99913428 T AT 99913428T AT E232396 T1 ATE232396 T1 AT E232396T1
- Authority
- AT
- Austria
- Prior art keywords
- oxidated
- beta
- thymosine beta
- present
- thymosine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9806632.7A GB9806632D0 (en) | 1998-03-28 | 1998-03-28 | Peptide factor |
PCT/GB1999/000833 WO1999049883A2 (en) | 1998-03-28 | 1999-03-29 | Oxidized thymosin beta 4 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE232396T1 true ATE232396T1 (de) | 2003-02-15 |
Family
ID=10829414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99913428T ATE232396T1 (de) | 1998-03-28 | 1999-03-29 | Oxydiertes thymosin beta 4 |
Country Status (15)
Country | Link |
---|---|
US (3) | US6602519B1 (de) |
EP (1) | EP1094833B1 (de) |
JP (1) | JP2002509893A (de) |
KR (1) | KR20010074461A (de) |
CN (2) | CN1178695C (de) |
AT (1) | ATE232396T1 (de) |
AU (1) | AU766493B2 (de) |
CA (1) | CA2325984A1 (de) |
DE (1) | DE69905368T2 (de) |
ES (1) | ES2192839T3 (de) |
GB (1) | GB9806632D0 (de) |
IL (1) | IL138665A0 (de) |
NZ (1) | NZ507642A (de) |
WO (1) | WO1999049883A2 (de) |
ZA (1) | ZA200005196B (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9806632D0 (en) * | 1998-03-28 | 1998-05-27 | Stevenson Robert | Peptide factor |
US20040067227A1 (en) * | 2001-11-02 | 2004-04-08 | Goldstein Allan L. | Inhibition or reversal of skin aging by actin-sequestering peptides |
CA2338928A1 (en) * | 1998-07-30 | 2000-02-10 | Hynda K. Kleinman | Thymosin .beta.4 promotes wound repair |
US20070191275A1 (en) * | 1998-07-30 | 2007-08-16 | Regenerx Biopharmaceuticals, Inc. | Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments |
WO2002036143A1 (en) | 2000-11-02 | 2002-05-10 | Regenerx Biopharmaceuticals, Inc. | Inhibition or reversal of skin aging by actin-sequestering peptides |
US20060100156A1 (en) * | 2004-10-01 | 2006-05-11 | Regenerx Biopharmaceuticals, Inc. | Cell nucleus-entering compositions |
US20070015698A1 (en) * | 1998-07-30 | 2007-01-18 | United States Of America As Represented By The Secretary Of Health | Treatment of skin, and wound repair, with thymosin beta 4 |
OA12431A (en) * | 2000-10-20 | 2006-04-19 | Beate Kehrel | Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. |
AU2002255736B2 (en) * | 2001-03-15 | 2006-08-31 | Regenerx, Biopharmaceuticals, Inc. | Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives |
CN101549148A (zh) * | 2001-08-29 | 2009-10-07 | 雷根内克斯生物制药有限公司 | 多肽在制备用于促进心内膜细胞向间质细胞转化的药物中的应用 |
AU2008201749B2 (en) * | 2002-02-06 | 2010-05-13 | Regenerx Biopharmaceuticals, Inc. | Treatment of Infections and Other Disorders |
EP2266595A3 (de) | 2002-02-06 | 2011-07-06 | Regenerx Biopharmaceuticals, Inc. | Behandlung von Infektionen und anderen Erkrankungen |
US20060264360A1 (en) * | 2002-04-12 | 2006-11-23 | Yale University Office Of Cooperstive Research | Anti-inflammatory and wound healing effects of lymphoid thymosin beta-4 |
US6821524B2 (en) * | 2002-06-03 | 2004-11-23 | Jan Marini Skin Research, Inc. | Cosmetic skin care compositions |
EP1613369A4 (de) * | 2003-03-31 | 2008-10-01 | Regenerx Biopharmaceuticals | Zusammensetzungen und verfahren zur abgabe von thymosin beta 4, analoga, isoformen und anderer derivate |
WO2005027958A1 (en) * | 2003-09-19 | 2005-03-31 | Imperial College Innovations Ltd | Thymosin-beta-sulphoxide as an immunosuppressive active agent |
CN1897965A (zh) * | 2003-12-22 | 2007-01-17 | 雷金纳克斯生物制药公司 | 反应性的化学剂、生物剂或毒素引起的生物反应或免疫反应的治疗方法或预防方法 |
JP2007537153A (ja) * | 2004-03-05 | 2007-12-20 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | 細胞外基質蓄積の治療または防止 |
US20080248993A1 (en) * | 2005-01-14 | 2008-10-09 | Regenerx Biopharmaceuticals, Inc. | Modified Beta Thymosin Peptides |
KR20080033939A (ko) | 2005-06-17 | 2008-04-17 | 리지너크스 바이오 파마소티컬스, 인코포레이티드 | 동결 건조된 형태이거나, 또는 동결 건조될 수 있는 형태인엘케이케이티이티 및/또는 엘케이케이티엔티 펩티드조성물들 |
AU2006269852A1 (en) * | 2005-07-19 | 2007-01-25 | Grannus Biosciences | Truncated oxidized thymosin beta4 and derivatives thereof |
ES2288118B1 (es) * | 2006-05-10 | 2008-11-01 | Bcn Peptides, S.A. | Procedimiento para sintetizar timosinas. |
CN101297965B (zh) * | 2008-06-16 | 2011-01-05 | 浙江省中医药研究院 | 胸腺肽β4在制备防治支气管哮喘药物中的应用 |
US20100247693A1 (en) * | 2009-03-24 | 2010-09-30 | Marini Jan L | Cosmetic formulation to treat rosacea telangiectasia |
US20110160144A1 (en) * | 2009-12-28 | 2011-06-30 | Perricone Nicholas V | Topical Acyl Glutathione Formulations |
US8580742B2 (en) | 2010-03-05 | 2013-11-12 | N.V. Perricone Llc | Topical glutathione formulations for menopausal skin |
US8609604B2 (en) | 2009-12-28 | 2013-12-17 | N.V. Perricone Llc | Methods of improving the appearance of aging skin |
JP5847418B2 (ja) | 2011-03-30 | 2016-01-20 | 富士フイルム株式会社 | 細胞接着性タンパク質 |
US9808654B2 (en) | 2013-02-11 | 2017-11-07 | Jan Marini Skin Research | Post procedure skin care gel and methods of use thereof |
CN110215513B (zh) * | 2018-11-15 | 2022-02-22 | 北京诺思兰德生物技术股份有限公司 | 经修饰的胸腺素β4在治疗放射性肠炎方面的用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US388234A (en) * | 1888-08-21 | Car-brake | ||
US3998798A (en) * | 1972-12-22 | 1976-12-21 | The Trustees Of The University Of Pennsylvania | Monellin, a sweet polypeptide derived from fruit of dioscoreophyllum cumminsii |
US4297276A (en) * | 1979-03-23 | 1981-10-27 | Hoffman-La Roche Inc. | Thymosin beta 3 and beta 4 |
US4389343A (en) | 1981-12-24 | 1983-06-21 | Hoffmann-La Roche Inc. | Immunopotentiating peptides from thymus |
US4388234A (en) * | 1981-12-28 | 1983-06-14 | Hoffmann-La Roche Inc. | Peptide isolation |
US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
US5593964A (en) * | 1993-10-07 | 1997-01-14 | The George Washington University Medical Center | Method of treating septic shock by preventing actin polymerization |
US5468729A (en) * | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
GB9806632D0 (en) * | 1998-03-28 | 1998-05-27 | Stevenson Robert | Peptide factor |
-
1998
- 1998-03-28 GB GBGB9806632.7A patent/GB9806632D0/en not_active Ceased
-
1999
- 1999-03-29 DE DE69905368T patent/DE69905368T2/de not_active Expired - Fee Related
- 1999-03-29 JP JP2000540846A patent/JP2002509893A/ja active Pending
- 1999-03-29 US US09/647,117 patent/US6602519B1/en not_active Expired - Fee Related
- 1999-03-29 WO PCT/GB1999/000833 patent/WO1999049883A2/en not_active Application Discontinuation
- 1999-03-29 AT AT99913428T patent/ATE232396T1/de not_active IP Right Cessation
- 1999-03-29 KR KR1020007010794A patent/KR20010074461A/ko not_active Application Discontinuation
- 1999-03-29 ES ES99913428T patent/ES2192839T3/es not_active Expired - Lifetime
- 1999-03-29 CN CNB998059579A patent/CN1178695C/zh not_active Expired - Fee Related
- 1999-03-29 IL IL13866599A patent/IL138665A0/xx not_active IP Right Cessation
- 1999-03-29 EP EP99913428A patent/EP1094833B1/de not_active Expired - Lifetime
- 1999-03-29 CN CNA2004100879091A patent/CN1644586A/zh active Pending
- 1999-03-29 AU AU31553/99A patent/AU766493B2/en not_active Ceased
- 1999-03-29 NZ NZ507642A patent/NZ507642A/en unknown
- 1999-03-29 CA CA002325984A patent/CA2325984A1/en not_active Abandoned
-
2000
- 2000-09-27 ZA ZA200005196A patent/ZA200005196B/en unknown
-
2003
- 2003-01-09 US US10/339,271 patent/US20040213772A1/en not_active Abandoned
-
2006
- 2006-06-14 US US11/452,738 patent/US20060229234A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2002509893A (ja) | 2002-04-02 |
CN1308543A (zh) | 2001-08-15 |
CN1178695C (zh) | 2004-12-08 |
AU766493B2 (en) | 2003-10-16 |
WO1999049883A3 (en) | 2001-02-22 |
WO1999049883A2 (en) | 1999-10-07 |
US6602519B1 (en) | 2003-08-05 |
AU3155399A (en) | 1999-10-18 |
NZ507642A (en) | 2003-10-31 |
ZA200005196B (en) | 2002-01-02 |
KR20010074461A (ko) | 2001-08-04 |
DE69905368T2 (de) | 2003-12-18 |
US20040213772A1 (en) | 2004-10-28 |
EP1094833B1 (de) | 2003-02-12 |
EP1094833A2 (de) | 2001-05-02 |
GB9806632D0 (en) | 1998-05-27 |
CA2325984A1 (en) | 1999-10-07 |
US20060229234A1 (en) | 2006-10-12 |
CN1644586A (zh) | 2005-07-27 |
DE69905368D1 (en) | 2003-03-20 |
IL138665A0 (en) | 2001-10-31 |
ES2192839T3 (es) | 2003-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE232396T1 (de) | Oxydiertes thymosin beta 4 | |
TR200002218T2 (tr) | 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri | |
MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
PT1028954E (pt) | Imidazoles substituidos uteis no tratamento de doencas inflamatorias | |
NO307968B1 (no) | Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav | |
IL130931A0 (en) | Small molecules useful in the treatment of inflammatory disease | |
NO894296D0 (no) | Fremgangsmaate for behandling av leddgikt og betennelsessykdommer. | |
DK209088D0 (da) | Medicinpraeparater, deres fremstilling og anvendelse | |
BG106095A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
YU60900A (sh) | Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja | |
CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
ES2184077T3 (es) | Nuevas fenantridinas sustituidas en la posicion 6. | |
NO972391L (no) | 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav | |
NO994431L (no) | Ny formulering | |
IT1290781B1 (it) | Agente attivo terapeutico per il trattamento di malattie degenerative neuronali. | |
TR200000455T2 (tr) | Alzheimer hastalığının tedavisinde fankinonun kullanılması. | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
ATE254595T1 (de) | 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten | |
EA200000909A1 (ru) | ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА | |
DE68906245T2 (de) | Therapeutisches Mittel gegen Aids. | |
NO20005548D0 (no) | Mykobakterieinhibitorer | |
MD980129A (en) | Antiherpetic remedy | |
GEP20074097B (en) | Use of specific dose of fondaparinux sodium for the treatment of acs | |
SE8802323D0 (sv) | 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1094833 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |